TY  - JOUR
AU  - Garrido, Pilar
AU  - Paz-Ares, Luis
AU  - Majem, Margarita
AU  - Morán, Teresa
AU  - Trigo, José Manuel
AU  - Bosch-Barrera, Joaquim
AU  - Garcίa-Campelo, Rosario
AU  - González-Larriba, José Luis
AU  - Sánchez-Torres, José Miguel
AU  - Isla, Dolores
AU  - Viñolas, Núria
AU  - Camps, Carlos
AU  - Insa, Amelia
AU  - Juan, Óscar
AU  - Massuti, Bartomeu
AU  - Paredes, Alfredo
AU  - Artal, Ángel
AU  - López-Brea, Marta
AU  - Palacios, José
AU  - Felip, Enriqueta
PY  - 2021
DO  - 10.1002/cam4.4135
UR  - http://hdl.handle.net/10668/18236
T2  - Cancer medicine
AB  - The aim of LungBEAM was to determine the value of a novel epidermal growth factor receptor (EGFR) mutation test in blood based on BEAMing technology to predict disease progression in advanced non-small cell lung cancer (NSCLC) patients treated with...
LA  - en
KW  - BEAMing
KW  - EGFR mutations
KW  - liquid biopsy
KW  - non-small cell lung carcinoma
KW  - Aged
KW  - Carcinoma, Non-Small-Cell Lung
KW  - ErbB Receptors
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Mutation
KW  - Prospective Studies
TI  - LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology.
TY  - research article
VL  - 10
ER  -